Skip to main content
SpringerLink
Log in

Arthralgias

  • Chapter
  • First Online:
Common Issues in Breast Cancer Survivors

  • 622 Accesses

Abstract

Musculoskeletal and joint pain are common in women, especially in perimenopausal and aging women. In women diagnosed with breast cancer, cancer treatment can be associated with musculoskeletal symptoms, particularly arthralgia, or non-inflammatory joint pain. Evaluation of new-onset arthralgia should include the history, physical examination, and laboratory evaluation for common non-inflammatory and inflammatory causes of joint pain. After chemotherapy, the self-limited syndrome of post-chemotherapy rheumatism may develop within 3–4 months of treatment and can last several months before it subsides. This syndrome may overlap with the start of adjuvant endocrine therapy, which may also be associated with arthralgia, particularly endocrine therapy with aromatase inhibitors. Aromatase inhibitor-associated arthralgia (AIAA) is common and difficult to treat. Regular exercise and adequate vitamin D levels can alleviate arthralgia and are also associated with improved well-being and better breast cancer and overall outcomes. Other approaches to relieve AIAA include switching to another endocrine therapy, use of a complementary intervention (like acupuncture or a supplement), and duloxetine. In cases where inflammatory arthritis is suspected or arthralgia is more persistent or severe than is typical for AIAA, referral to a rheumatologist is warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Watt FE. Musculoskeletal pain and menopause. Post Reprod Health. 2018;24(1):34–43.

    Article  PubMed  Google Scholar 

  2. Alpay-Kanitez N, Celik S, Bes C. Polyarthritis and its differential diagnosis. Eur J Rheumatol. 2018;6(4):167–73.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Symmons DPM. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. Best Pract Res Clin Rheumatol. 2002;16(5):707–22.

    Article  PubMed  Google Scholar 

  4. Grassi W, et al. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998;27 Suppl 1:p. S18–S24.

    Google Scholar 

  5. Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–59.

    Google Scholar 

  6. Magliano M. Menopausal arthralgia: fact or fiction. Maturitas. 2010;67(1):29–33.

    Article  PubMed  Google Scholar 

  7. Kumar B, Lenert P. Joint hypermobility syndrome: recognizing a commonly overlooked cause of chronic pain. Am J Med. 2017;130(6):640–7.

    Article  PubMed  Google Scholar 

  8. Loprinzi CL, Duffy J, Ingle JN. Postchemotherapy rheumatism. J Clin Oncol. 1993;11:768.

    Article  CAS  PubMed  Google Scholar 

  9. Amiri AH, Rafiei A. Analysis of patients with post-chemotherapy arthralgia and arthritis in breast cancer. Indian J Med Sci. 2010;64(5):197–203.

    Article  PubMed  Google Scholar 

  10. Amiri AH, Jaferian S. Post-chemotherapy arthralgia and arthritis in lung cancer. South Asian J Cancer. 2012;1(2):72–5.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kim MJ, et al. Chemotherapy-related arthropathy. J Rheumatol. 2006;33(7):1364–8.

    CAS  PubMed  Google Scholar 

  12. Almoallim H, et al. Clinical characteristics and outcomes of cancer patients with post-chemotherapy arthritis: a retrospective case series report. Open Access Rheumatol. 2017;9:111–6.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Burstein HJ. Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007;16(3):223–34.

    Article  PubMed  Google Scholar 

  14. Dowsett M, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–52.

    Google Scholar 

  15. Forbes JF, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.

    Article  PubMed  CAS  Google Scholar 

  16. Mouridsen H, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766–76.

    Article  CAS  PubMed  Google Scholar 

  17. Coates AS, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007;25(5):486–92.

    Article  CAS  PubMed  Google Scholar 

  18. Coombes RC, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369(9561):559–70.

    Article  CAS  PubMed  Google Scholar 

  19. Braithwaite RS, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003;18(11):937.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Henry NL, Giles JT, Stearns V. Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology (Williston Park). 2008;22(12):1401–8.

    Google Scholar 

  21. Coleman RE, et al. Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev. 2008;34(3):275–82.

    Article  CAS  PubMed  Google Scholar 

  22. Crew KD, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877–83.

    Article  PubMed  Google Scholar 

  23. Lombard JM, et al. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options. Support Care Cancer. 2016;24(5):2139–46.

    Article  PubMed  Google Scholar 

  24. Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013;24(6):1443–9.

    Article  CAS  PubMed  Google Scholar 

  25. Donnellan PP, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001;19(10):2767.

    Article  CAS  PubMed  Google Scholar 

  26. Presant CA, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer. 2007;7(10):775–8.

    Article  CAS  PubMed  Google Scholar 

  27. Howell A, et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60.

    Article  CAS  PubMed  Google Scholar 

  28. Coombes RC, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004;350(11):1081.

    Google Scholar 

  29. Thurlimann B, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747–57.

    Google Scholar 

  30. Goss PE, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793.

    Google Scholar 

  31. Boonstra A, et al. Arthralgia during aromatase inhibitor treatment in early breast cancer patients: prevalence, impact, and recognition by healthcare providers. Cancer Nurs. 2013;36(1):52–9.

    Article  PubMed  Google Scholar 

  32. Dizdar O, et al. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin Oncol. 2009;27(30):4955–60.

    Article  PubMed  Google Scholar 

  33. Friedman CF, et al. Functional disability and aromatase inhibitor-associated arthralgia in breast cancer survivors. J Clin Oncol. 2010;28(15S).

    Google Scholar 

  34. Mao JJ, et al. Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer. 2009;115(16):3631–9.

    Article  CAS  PubMed  Google Scholar 

  35. Oberguggenberger A, et al. Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs). Breast Cancer Res Treat. 2011;128(2):553–61.

    Article  CAS  PubMed  Google Scholar 

  36. Kanematsu M, et al. The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia. BMC Cancer. 2011;11:436.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Singer O, et al. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res (Hoboken). 2012;64(12):1910–8.

    Google Scholar 

  38. Kimmick GG, et al. Musculoskeletal side effects over time and association with adherence in women taking neoadjuvant letrozole for estrogen receptor positive DCIS: CALGB 40903 (Alliance). Breast Cancer Res Treat. 2019; SABCS 2019(P5-14-17).

    Google Scholar 

  39. Castel LD, et al. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer. 2013;119(13):2375–82.

    Article  CAS  PubMed  Google Scholar 

  40. Sestak I, et al. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol. 2008;9(9):866–72.

    Article  PubMed  Google Scholar 

  41. Renshaw L, et al. Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. Breast Cancer Res Treat. 2007;106:S108–S109.

    Google Scholar 

  42. Morales L, et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat. 2007;104(1):87–91.

    Google Scholar 

  43. Laroche F, et al. Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study. J Pain. 2014;15(3):293–303.

    Article  CAS  PubMed  Google Scholar 

  44. Spagnolo F, et al. Anastrozole-induced carpal tunnel syndrome: results from the international breast cancer intervention study II prevention trial. J Clin Oncol. 2016;34(2):139–43.

    Google Scholar 

  45. Sestak I, Sapunar F, Cuzick J. Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol. 2009;27(30):4961–5.

    Article  CAS  PubMed  Google Scholar 

  46. Papadimitriou K, et al. Bilateral de quervain syndrome after aromatase inhibitor administration: a case report and review of the literature. Case Rep Med. 2012;2012:810428.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lee JH, Kim JY, Kim CH. A case of bilateral trigger thumbs secondary to aromatase inhibitor. Yonsei Med J. 2015;56(4):1167–9.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Murphy CC, et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Fontein DB, et al. High non-compliance in the use of letrozole after 2.5 years of extended adjuvant endocrine therapy. Results from the IDEAL randomized trial. Eur J Surg Oncol. 2012;38(2):110–7.

    Google Scholar 

  50. Hershman DL, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–37.

    Article  CAS  PubMed  Google Scholar 

  51. Henry NL, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat. 2008;111(2):365–72.

    Article  CAS  PubMed  Google Scholar 

  52. Moy B, et al. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol. 2006;17(11):1637–43.

    Article  CAS  PubMed  Google Scholar 

  53. Xu J, et al. Natural history of menopause symptoms in primary care patients: a MetroNet study. J Am Board Fam Pract. 2005;18(5):374–82.

    Article  PubMed  Google Scholar 

  54. Fuh JL, et al. Quality of life and menopausal transition for middle-aged women on Kinmen island. Qual Life Res. 2003;12(1):53–61.

    Article  CAS  PubMed  Google Scholar 

  55. Bingefors K, Isacson D. Epidemiology, co-morbidity, and impact on health-related quality of life of self-reported headache and musculoskeletal pain--a gender perspective. Eur J Pain. 2004;8(5):435–50.

    Article  PubMed  Google Scholar 

  56. Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol. 2007;14(Suppl 1):S11–9.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Younus J, Kligman L. Management of aromatase inhibitor-induced arthralgia. Curr Oncol. 2010;17(1):87–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Din OS, et al. Current opinion of aromatase inhibitor-induced arthralgia in breast cancer in the UK. Clin Oncol (R Coll Radiol). 2011;23(10):674–80.

    Article  CAS  Google Scholar 

  59. Menas P, et al. Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. J Oncol Pharm Pract. 2012;18(4):387–93.

    Article  CAS  PubMed  Google Scholar 

  60. Park SH, Knobf MT, Sutton KM. Etiology, assessment, and management of aromatase inhibitor-related musculoskeletal symptoms. Clin J Oncol Nurs. 2012;16(3):260–6.

    Article  PubMed  Google Scholar 

  61. Yang GS, et al. Interventions for the treatment of aromatase inhibitor-associated arthralgia in breast cancer survivors: a systematic review and meta-analysis. Cancer Nurs. 2017;40(4):E26–41.

    Article  PubMed  Google Scholar 

  62. Dent SF, et al. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Res Treat. 2011;126(2):295–310.

    Article  CAS  PubMed  Google Scholar 

  63. Somers TJ, Wren AA, Shelby RA. The context of pain in arthritis: self-efficacy for managing pain and other symptoms. Curr Pain Headache Rep. 2012;16(6):502–8.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Jerant A, Franks P, Kravitz RL. Associations between pain control self-efficacy, self-efficacy for communicating with physicians, and subsequent pain severity among cancer patients. Patient Educ Couns. 2011;85(2):275–80.

    Google Scholar 

  65. Johannsen M, et al. The efficacy of psychosocial intervention for pain in breast cancer patients and survivors: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;138(3):675–90.

    Google Scholar 

  66. Sheinfeld Gorin S, et al. Meta-analysis of psychosocial interventions to reduce pain in patients with cancer. J Clin Oncol. 2012;30(5):539–47.

    Google Scholar 

  67. Kelleher SA, et al. A behavioral cancer pain intervention: A randomized noninferiority trial comparing in-person with videoconference delivery. Psychooncology. 2019;28(8):1671–8.

    Google Scholar 

  68. Shelby RA, et al. Testing a behavioral intervention to improve adherence to adjuvant endocrine therapy (AET). Contemp Clin Trials. 2019;76:120–131.

    Google Scholar 

  69. Khan QJ, O’Dea AP, Sharma P, Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol. 2010;2010:1–8.

    Google Scholar 

  70. Cuzick, J, et al. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol. 2008;9(12):1143–8.

    Google Scholar 

  71. Irwin ML et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104–11.

    Google Scholar 

  72. DeNysschen CA et al. Exercise intervention in breast cancer patients with aromatase inhibitor-associated arthralgia: a pilot study. Eur J Cancer Care (ENgl). 2014; 23(4):493–501.

    Google Scholar 

  73. Baglia MS et al. Endocrine-related quality of life in a randomized trial of exercise on aromatase inhibitor-induced arthralgias in breast cancer survivors. Cancer. 2019;125(13):2262–71.

    Google Scholar 

  74. Sisto SA, Malanga G. Osteoarthritis and therapeutic exercise. Am J Phys Med Rehabil. 2006;85(11 Suppl):S69–78.

    Google Scholar 

  75. Thomas KS et al. Home based exercise programme for knee pain and knee osteoarthritis: randomised controlled trial. BMJ. 2002;325(7367):752.

    Google Scholar 

  76. Ballard-Barbash R et al. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst. 2012;104(11):815–40.

    Google Scholar 

  77. Rock CL et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012;62(4):243–74.

    Google Scholar 

  78. Demark-Wahnefried W et al. Results of a diet/exercise feasibility trial to prevent adverse body composition change in breast cancer patients on adjuvant chemotherapy. Clin Breast Cancer. 2008;8(1):70–9.

    Google Scholar 

  79. Lima LV, Abner TSS, Sluka KA. Does exercise increase or decrease pain? Central mechanisms underlying these two phenomena. J Physiol. 2017;595(13):4141–50.

    Google Scholar 

  80. Polaski AM et al. Exercise-induced hypoalgesia: A meta-analysis of exercise dosing for the treatment of chronic pain. PLoS One. 2019;14(1):e0210418.

    Google Scholar 

  81. Nyrop KA, et al. Feasibility and promise of a 6-week program to encourage physical activity and reduce joint symptoms among elderly breast cancer survivors on aromatase inhibitor therapy. J Geriatr Oncol. 2014;5(2):148–55.

    Google Scholar 

  82. Hasan N, Sonnenschein C, Soto AM. Vitamin D3 constrains estrogen’s effects and influences mammary epithelial organization in 3D cultures. Sci Rep. 2019;9(1):7423.

    Google Scholar 

  83. Jurutka PW et al. Vitamin D receptor: key roles in bone mineral pathophysiology, molecular mechanism of action, and novel nutrient ligands. J Bone Miner Res. 2007;22 Suppl 2:V2–10.

    Google Scholar 

  84. Crew KD et al. Association between plasma 25-hydroxyvitamin D and breast cancer risk. Cancer Prev Res (Phila). 2009;2(6):598–604.

    Google Scholar 

  85. Arvold DS et al. Correlation of symptoms with vitamin D deficiency and symptom response to cholecalciferol treatment: a randomized controlled trial. Endocr Pract. 2009;15(3):203–12.

    Google Scholar 

  86. Khan QJ, et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat. 2009;119(1):111–8.

    Google Scholar 

  87. Prieto-Alhambra D et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat. 2011;125(3):869–78.

    Google Scholar 

  88. Prieto-Alhambra D, Javaid MK. Aromatase inhibitor induced arthralgia: is vitamin D deficiency responsibible? Maturitas. 2011;69(1):3–4.

    Google Scholar 

  89. Rastelli AL et al. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-bline, placebo-controlled, randomized trial. Breast Cancer Res Treat. 2011;129(1):107–16.

    Google Scholar 

  90. Razzaque MS. Can adverse effects of excessive vitamin D supplementation occur without developing hypervitaminosis D? J Steroid Biochem Mol Biol. 2018;180:81–6.

    Google Scholar 

  91. Sanders KM et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA. 2010;202(18):1815–22.

    Google Scholar 

  92. Durup D et al. A reverse J-shaped assocition of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J Clin Endocrinol Metab. 2012;97(8):2644–52.

    Google Scholar 

  93. Kimmick G, et al. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast. 2015;24(5):630–6.

    Google Scholar 

  94. Group, B.I.G.C., et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766–76.

    Google Scholar 

  95. Briot K, et al. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat. 2010;120(1):127–34.

    Article  CAS  PubMed  Google Scholar 

  96. Garreau JR, et al. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg. 2006;192(4):496–8.

    Article  CAS  PubMed  Google Scholar 

  97. Sitlinger A, et al. Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. J Geriatr Oncol. 2019;10(2):317–21.

    Google Scholar 

  98. Morales L et al. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitorassociated arthralgia syndrome. J Clin Oncol. 2008;26(19):3147–52.

    Google Scholar 

  99. Kanesvaran R, White HK, Kimmick GG. (AI) Can’t get off my chair. J Am Geriatr Soc. 2012;60(10):1978–9.

    Article  PubMed  Google Scholar 

  100. Neuhouser ML, et al. Use of complementary and alternative medicine and breast cancer survival in the Health, Eating, Activity, and Lifestyle Study. Breast Cancer Res Treat. 2016;160(3):539–46.

    Article  PubMed  PubMed Central  Google Scholar 

  101. Cassileth BR, Vickers AJ. High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care. J Clin Oncol. 2005;23(12):2590–2.

    Article  PubMed  Google Scholar 

  102. Velicer CM, Ulrich CM. Vitamin and mineral supplement use among US adults after cancer diagnosis: a systematic review. J Clin Oncol. 2008;26(4):665–73.

    Article  CAS  PubMed  Google Scholar 

  103. Sierpina VS, Frenkel MA. Acupuncture: a clinical review. South Med J. 2005;98(3):330–7.

    Article  PubMed  Google Scholar 

  104. Lim HD, et al. Anti-inflammatory effects of acupuncture stimulation via the vagus nerve. PLoS One. 2016;11(3):e0151882.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  105. Sandberg M, et al. Effects of acupuncture on skin and muscle blood flow in healthy subjects. Eur J Appl Physiol. 2003;90(1–2):114–9.

    Article  PubMed  Google Scholar 

  106. Madsen MV, Gotzsche PC, Hrobjartsson A. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. BMJ. 2009;338:a3115.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Ezzo J, et al. Acupuncture for osteoarthritis of the knee: a systematic review. Arthritis Rheum. 2001;44(4):819–25.

    Article  CAS  PubMed  Google Scholar 

  108. Zhang Y, et al. Acupuncture use among American adults: what acupuncture practitioners can learn from national health interview survey 2007? Evid Based Complement Alternat Med. 2012;2012:710750.

    PubMed  PubMed Central  Google Scholar 

  109. Crew KD, et al. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients. J Cancer Surviv. 2007;1(4):283–91.

    Article  PubMed  Google Scholar 

  110. Crew KD, et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010;28(7):1154–60.

    Article  CAS  PubMed  Google Scholar 

  111. Bao T, et al. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast Cancer Res Treat. 2013;138(1):167–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Hershman DL, et al. Effect of acupuncture vs sham acupuncture or waitlist control on joint pain related to aromatase inhibitors among women with early-stage breast cancer: a randomized clinical trial. JAMA. 2018;320(2):167–76.

    Article  PubMed  PubMed Central  Google Scholar 

  113. Mao JJ, et al. Feasibility trial of electroacupuncture for aromatase inhibitor-related arthralgia in breast cancer survivors. Integr Cancer Ther. 2009;8(2):123–9.

    Article  PubMed  Google Scholar 

  114. Mao JJ, et al. A randomised trial of electro-acupuncture for arthralgia related to aromatase inhibitor use. Eur J Cancer. 2014;50(2):267–76.

    Article  CAS  PubMed  Google Scholar 

  115. Oh B, et al. Acupuncture for treatment of arthralgia secondary to aromatase inhibitor therapy in women with early breast cancer: pilot study. Acupunct Med. 2013;31(3):264–71.

    Article  CAS  PubMed  Google Scholar 

  116. Bae K, et al. Acupuncture for aromatase inhibitor-induced arthralgia: a systematic review. Integr Cancer Ther. 2015;14(6):496–502.

    Article  CAS  PubMed  Google Scholar 

  117. Chien TJ, et al. Acupuncture for treating aromatase inhibitor-related arthralgia in breast cancer: a systematic review and meta-analysis. J Altern Complement Med. 2015;21(5):251–60.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Culos-Reed SN, et al. A pilot study of yoga for breast cancer survivors: physical and psychological benefits. Psychooncology. 2006;15(10):891–7.

    Article  PubMed  Google Scholar 

  119. Carson JW, et al. Yoga of awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. Support Care Cancer. 2009;17(10):1301–9.

    Article  PubMed  Google Scholar 

  120. Ulger O, Yagli NV. Effects of yoga on the quality of life in cancer patients. Complement Ther Clin Pract. 2010;16(2):60–3.

    Article  PubMed  Google Scholar 

  121. Galantino ML, et al. Impact of yoga on functional outcomes in breast cancer survivors with aromatase inhibitor-associated arthralgias. Integr Cancer Ther. 2012;11(4):313–20.

    Article  PubMed  Google Scholar 

  122. Galantino ML, et al. A qualitative exploration of the impact of yoga on breast cancer survivors with aromatase inhibitor-associated arthralgias. Explore (NY). 2012;8(1):40–7.

    Article  Google Scholar 

  123. Peppone LJ, et al. The effect of YOCAS(c)(R) yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy. Breast Cancer Res Treat. 2015;150(3):597–604.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Lippiello L, et al. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res. 2000;381:229–40.

    Article  Google Scholar 

  125. Clegg DO, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808.

    Article  CAS  PubMed  Google Scholar 

  126. Greenlee H, et al. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer. 2013;21(4):1077–87.

    Article  PubMed  Google Scholar 

  127. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;1:CD007115.

    Google Scholar 

  128. Henry NL, et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer. 2011;117(24):5469–75.

    Article  CAS  PubMed  Google Scholar 

  129. Henry NL, et al. Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202. J Clin Oncol. 2018;36(4):326–32.

    Article  CAS  PubMed  Google Scholar 

  130. Uhlenbruck G, et al. Reduced side-effects of adjuvant hormone therapy in breast cancer patients by complementary medicine. In Vivo. 2010;24(5):799–802.

    CAS  PubMed  Google Scholar 

  131. Beuth J, et al. Large-scale survey of the impact of complementary medicine on side-effects of adjuvant hormone therapy in patients with breast cancer. In Vivo. 2016;30(1):73–5.

    CAS  PubMed  Google Scholar 

  132. Beuth J, et al. Complementary medicine on side-effects of adjuvant hormone therapy in patients with breast cancer. In Vivo. 2013;27(6):869–71.

    CAS  PubMed  Google Scholar 

  133. Chino A, et al. A case of aromatase inhibitor (anastrozole)-induced side-effects successfully treated with Kampo medicines. J Altern Complement Med. 2011;17(11):1075–7.

    Article  PubMed  Google Scholar 

  134. Zhang Q, Tang D, Zhao H. Immunological therapies can relieve aromatase inhibitor-related joint symptoms in breast cancer survivors. Am J Clin Oncol. 2010;33(6):557–60.

    Article  CAS  PubMed  Google Scholar 

  135. Kubo M, et al. Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res. 2012;32(6):2331–6.

    CAS  PubMed  Google Scholar 

  136. Galantino ML, et al. Tai chi for well-being of breast cancer survivors with aromatase inhibitor-associated arthralgias: a feasibility study. Altern Ther Health Med. 2013;19(6):38–44.

    PubMed  Google Scholar 

  137. Leslie CA, et al. Dietary fish oil modulates macrophage fatty acids and decreases arthritis susceptibility in mice. J Exp Med. 1985;162(4):1336–49.

    Article  CAS  PubMed  Google Scholar 

  138. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007;129(1–2):210–23.

    Article  CAS  Google Scholar 

  139. Maroon JC, Bost JW. Omega-3 fatty acids (fish oil) as an anti-inflammatory: an alternative to nonsteroidal anti-inflammatory drugs for discogenic pain. Surg Neurol. 2006;65(4):326–31.

    Article  PubMed  Google Scholar 

  140. Hershman DL, et al. Randomized multicenter placebo-controlled trial of omega-3 fatty acids for the control of aromatase inhibitor-induced musculoskeletal pain: SWOG S0927. J Clin Oncol. 2015;33(17):1910–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, Duke University School of Medicine/Duke Cancer Institute, Durham, NC, USA

    Gretchen G. Kimmick

  2. Medical Oncology, Duke University Medical Center/Duke Cancer Institute, Durham, NC, USA

    Rachel Anne Pienknagura

  3. Rheumatology and Immunology, Duke University Medical Center, Durham, NC, USA

    Sophia C. Weinmann

Authors
  1. Gretchen G. Kimmick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel Anne Pienknagura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sophia C. Weinmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gretchen G. Kimmick .

Editor information

Editors and Affiliations

  1. Medical Oncology, Duke University School of Medicine/Duke Cancer Institute, Durham, NC, USA

    Gretchen G. Kimmick

  2. Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA

    Rebecca A. Shelby

  3. Duke University School of Medicine Duke Cancer Network, Durham, NC, USA

    Linda M. Sutton

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kimmick, G.G., Pienknagura, R.A., Weinmann, S.C. (2021). Arthralgias. In: Kimmick, G.G., Shelby, R.A., Sutton, L.M. (eds) Common Issues in Breast Cancer Survivors. Springer, Cham. https://doi.org/10.1007/978-3-030-75377-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-75377-1_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-75376-4

  • Online ISBN: 978-3-030-75377-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation